FDA Accepts Atox Bio’s Reltecimod to Treat Suspected Organ Dysfunction/Failure re “Flesh-Eating Disease”
The U.S. Food and Drug Administration (FDA) has accepted to Atox Bio’s filing of the New Drug Application (NDA) for Reltecimod with a Prescription Drug User Fee Act (PDUFA) date…
Continue Reading
FDA Accepts Atox Bio’s Reltecimod to Treat Suspected Organ Dysfunction/Failure re “Flesh-Eating Disease”
